---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001517"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:26:32.456713+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart

## Summary
- Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.
- CEO Harout Semerjian and CFO Brian Hahn ceased employment on Feb 21, 2025; severance payments of $1,365,456 and $480,991 respectively.
- Five directors (Goldberg, Jackson, King, Koenig, Semerjian) resigned Feb 21, 2025; no disagreement with company operations.
- Semerjian consulting: $700/hr for 12 months; Hahn consulting: $15,000/month through change in control or Sep 30, 2025.
- Company is pursuing a merger with Crescent Biopharma (Form S-4 filed).

## SEC filing metadata
- accession: 0001558370-25-001517
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/glyc-20250219x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001517
- JSON: https://secwatch.observer/filing/0001558370-25-001517.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001517.txt

## Source-grounded claims
- claim_id: 226bee0065
  claim: Rachel King resigned as Director at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- claim_id: 290de6af05
  claim: Harout Semerjian resigned as Director at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- claim_id: 3e0859b4b4
  claim: Mark Goldberg resigned as Director at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- claim_id: 55d17dab71
  claim: Scott Jackson resigned as Director at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- claim_id: 816677156a
  claim: Brian Hahn departed as Chief Financial Officer at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- claim_id: 860c9512d0
  claim: Harout Semerjian departed as Chief Executive Officer at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm
- claim_id: fdfccd119c
  claim: Scott Koenig resigned as Director at CRESCENT BIOPHARMA, INC..
  evidence_excerpt: each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.